Talaris Therapeutics (TALS) (~$79MM market cap) is one other failed biotech that just lately introduced they’re pursuing of strategic alternate options after discontinuing a section 3 trial and a section 2 trial for his or her cell remedy supposed to assist these with kidney transplants. Talaris hasn’t utterly raised the white flag, however shut, they’re nonetheless enrolling sufferers in one other section 2 trial, this time for scleroderma, and solely laid off one-third of their workforce (112 staff as of the final 10-Ok). Nonetheless, Talaris is buying and selling properly beneath money even in a conservative 4 quarters of money burn situation, any trace of a liquidation or different company motion might spur the shares increased.
Talaris disclosed of their latest 8-Ok that that they had $181.3MM in money and securities remaining. Utilizing the implied This autumn money burn price for the rest of 2023, I get a proforma web money quantity of $129.3MM towards a present market cap of $79MM. One profit right here is the presence of Blackstone’s Life Sciences arm (Clarus Ventures) which owns just below 20% of the shares, hopefully sufficient to look out for shareholder worth in the course of the course of.
Disclosure: I personal shares of TALS
